Antifungal Resistance Trends of Candida auris Clinical Isolates in New York and New Jersey from 2016 to 2020.
Journal: Antimicrobial Agents And Chemotherapy
Published:
Abstract
About 55% of U.S. Candida auris clinical cases were reported from New York and New Jersey from 2016 through 2020. Nearly all New York-New Jersey clinical isolates (99.8%) were fluconazole resistant, and 50% were amphotericin B resistant. Echinocandin resistance increased from 0% to 4% and pan-resistance increased from 0 to <1% for New York C. auris clinical isolates but not for New Jersey, highlighting the regional differences.
Authors
Shannon Kilburn, Gabriel Innes, Monica Quinn, Karen Southwick, Belinda Ostrowsky, Jane Greenko, Emily Lutterloh, Rebecca Greeley, Reed Magleby, Vishnu Chaturvedi, Sudha Chaturvedi